Jeff Smith’s activist hedge fund Starboard Value LP has formally called for a special meeting of Depomed shareholders as it seeks to oust the company’s entire board of directors.  Starboard, which owns 9.9% of the pharmaceutical company, raised concerns in an April letter about the firm’s corporate governance, capital allocation decisions and what it termed were “egregious” actions by the board to prevent a strategic acquisition. The company came under particular criticism from Starboard for exploring reincorporation in Delaware, which the hedge fund alleged was an attempt by the board to entrench itself and further suppress shareholder rights.  The company...